Meeting
2023 ASCO Annual Meeting
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
Authors
Luis G. Paz-Ares
Hospital Universitario, 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
Luis G. Paz-Ares , Carl Michael Gay , Caicun Zhou , Terufumi Kato , Luis Corrales , Karl Redhead , Ahmadur Rahman , Denise Bradley , Elizabeth Theogaraj , Katherine E. Hutchinson , Sarah M. Shagan , Benjamin J. Solomon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05170204
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8605)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8605
Abstract #
TPS8605
Poster Bd #
229a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
First Author: David Planchard
Poster
2019 ASCO Annual Meeting
PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.
First Author: Jeffrey D. Bradley
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Healthcare provider awareness and integration of immunotherapy for stage III NSCLC.
First Author: Rachael Andrie
Poster
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
First Author: Amin Nassar